Drug Profile
COVID-19 therapeutic- CEL-SCI Corporation
Latest Information Update: 04 Dec 2020
Price :
$50
*
At a glance
- Originator CEL-SCI Corporation
- Class Antivirals; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 01 Dec 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Injection) before December 2020
- 01 Dec 2020 Immunogenicity data from a preclinical trial in COVID-2019 infections released by CEL-SCI Corporation
- 27 Jul 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route)